SCHEMBL3941941

SCHEMBL3941941

COC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(N(CCN(C)C)C(C)=O)cc1)c1ccc2c(c1)OCCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 2/20 0.36
USP2 O75604 1/20 0.36
KDM4E B2RXH2 2/20 0.36
TRPV1 Q8NER1 1/20 0.36
MAOB P27338 1/20 0.36
HPGD P15428 1/20 0.36
GAA P10253 2/20 0.35
RAD52 P43351 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3941940 1.00 MAPT (0.39) MAPTNPC1RAB9ASMN1; SMN2CASP3
SCHEMBL3933011 0.94 MAPT (0.45) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3933010 0.94 MAPT (0.45) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3930642 0.91 MAOB (0.41) MAPTNPC1RAB9ASMN1; SMN2CASP3
SCHEMBL3932485 0.91 MEN1 (0.42) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3930645 0.91 MAOB (0.41) MAPTNPC1RAB9ASMN1; SMN2CASP3
SCHEMBL3930574 0.91 MEN1 (0.42) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL3935699 0.91 KMT2A (0.34) MAPTNPC1RAB9ASMN1; SMN2CASP3
SCHEMBL3935694 0.91 KMT2A (0.34) MAPTNPC1RAB9ASMN1; SMN2CASP3
SCHEMBL3933076 0.90 MAPT (0.44) MAPTNPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US claimed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US claimed
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 MAPT 1798/4885NPC1 4723/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.